Revance Therapeutics announced in early December that its longacting neuromodulator daxibotulinumtoxinA for Injection RT002 delivered positive results in a phase 3 study for treatment of moderate-to-severe glabellar lines.
Revance Therapeutics announced in early December that its longacting neuromodulator daxibotulinumtoxinA for Injection RT002, which features the company’s proprietary stabilizing excipient peptide technology, delivered positive results in a phase 3 study for treatment of moderate-to-severe glabellar lines. Use of RT002 was well-tolerated in more than 3,800 treatments studied, and the average time to return to baseline glabellar line severity was 28 weeks, according to a Revance news release.
“Revance is entering 2019 with tremendous momentum on multiple fronts,” says Dan Browne, president and chief executive officer at Revance in a company press release. “We have an exciting ensemble of late-stage clinical trials underway for our next-generation neuromodulator and are operating a U.S.-based, commercial-scale drug substance and drug product facility to manufacture a broad range of proprietary neuromodulation formulations. We also have an active collaboration for the introduction of RT002 in China and another to develop a biosimilar to Botox. Strategically, as we anticipate entering the market with RT002 in 2020, we intend to set a new standard in neuromodulators, focused on providing patients with the ability to safely alleviate the appearance of frown lines with just two or fewer treatments per year.”
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program. December 4, 2018. Available at: https://investors.revance.com/news-releases/news-release-details/revances-rt002-demonstratesunprecedented-efficacy-and-duration. Accessed February 2019.